CMBA
CAPR icon

C.M. Bidwell & Associates’s Capricor Therapeutics CAPR Stock Holding History

C.M. Bidwell & Associates’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-43
Closed -$408 – 459
2025
Q1 		$408 Buy
+43
New +$597 ﹤0.01% 420

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return
BDF
Black Diamond Financial Towson, Maryland $916M AUM 15.95% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

C.M. Bidwell & Associates's CAPR Position: Q2 2025 in Review

C.M. Bidwell & Associates sold out of Capricor Therapeutics (CAPR) in Q2 2025, closing a stake of 43 shares — an estimated $408 sold.

C.M. Bidwell & Associates first reported a position in CAPR in Q1 2025 and held it in 1 quarter. The position peaked at $408 in Q1 2025. 107 funds tracked by Wall St. Rank hold CAPR as of Q2 2025.

  • C.M. Bidwell & Associates reported no remaining Capricor Therapeutics position as of Q2 2025 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 43 Capricor Therapeutics shares in Q2 2025, an estimated $408.
  • C.M. Bidwell & Associates first reported a position in Capricor Therapeutics in Q1 2025 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Capricor Therapeutics position peaked at $408 in Q1 2025.
  • 107 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2025, filed 14 Aug 2025.